Shanghai Junshi Biosciences Co.,Ltd. (688180.SH) has announced that the indication for its product toripalimab injection (brand name: Tuoyi®, product code: JS001) in combination with disitamab vedotin for HER2-expressing locally advanced or metastatic urothelial carcinoma has been successfully included in the Class B category of the National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug Directory (2026 edition).

The new edition of the national medical insurance directory will officially take effect on January 1, 2027.

As of the disclosure date of the announcement, all 13 indications of Tuoyi® approved for marketing in mainland China have been included in the national medical insurance directory.

It is the only anti-PD-1 monoclonal antibody drug in the directory used for the treatment of triple-negative breast cancer, melanoma, first-line renal cancer, and first-line urothelial carcinoma.